Kaftrio

Active substance ELX/TEZ/IVA and IVA alone
Holder Vertex Pharmaceuticals (Netherlands) BV
Status Running
Indication Cystic fibrosis (CF) in patients from 6 to 11 years old who are homozygous for F508del (F/F genotype) or heterozygous for F508del and a minimal function (F/MF genotype) mutation.
Public documents Approbation
  Approbation amendment
  Information for the patient
  Informed consent
Last update 15/09/2022

 

Last updated on 28/09/2022